Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced

Response Pharmaceuticals announced positive top-line Phase II results for RDX-002, a selective inhibitor of intestinal microsomal triglyceride transfer protein (iMTP), which is being developed to help maintain weight loss after stopping GLP-1 agonists like semaglutide (Wegovy) and tirzepatide (Zepbound)134.

The 68-patient, 12-week, randomized study found that patients on RDX-002 had significantly reduced postprandial triglycerides (–227.3 mghr/dL vs. +64.1 mghr/ml for placebo; –93.5% LS mean difference; p<0.001)3.

Weight regain was ~34% lower in the RDX-002 group, with a mean increase of 2.92% versus higher gains in the placebo group (p=0.019)14.

Additional improvements were observed in blood pressure, inflammatory markers (including high-sensitivity C-reactive protein), and LDL cholesterol142.

RDX-002 demonstrated a favorable safety profile:
only mild-to-moderate gastrointestinal side effects, no serious adverse events, and no trial discontinuations due to adverse effects124.

Sustained efficacy is being further assessed in an ongoing 24-week open-label extension study4.

Full detailed results will be presented at an upcoming scientific meeting1.

Sources:

1. https://www.thepharmaletter.com/pharmaceutical/response-offers-positive-phase-ii-data-for-postglp1-obesity

2. https://www.bariatricnews.net/post/response-pharmaceuticals-completion-enrolment-of-study-evaluating-rdx-002-post-glp-1-weight-rebound

3. https://www.biospace.com/press-releases/response-pharmaceuticals-announces-positive-top-line-results-from-phase-2-study-of-rdx-002-in-post-glp-1-management

4. https://www.businesswire.com/news/home/20250813869741/en/Response-Pharmaceuticals-Announces-Positive-Top-Line-Results-From-Phase-2-Study-of-RDX-002-in-Post-GLP-1-Management